Boston-based Seaport is preparing for an IPO to advance its lead depression candidate, SPT-300 (GlyphAllo), aimed at treating major depressive disorder. The funds will be allocated for a Phase IIb study and subsequent Phase III trials, with top results expected next year. Additionally, money will support SPT-320 for generalized anxiety disorder and SPT-348, a prodrug of a non-hallucinogenic LSD analog. Seaport reported having $233.7 million in cash and investments to sustain operations through 2026.
Meanwhile, Hemab is also moving towards a public offering to support its lead asset, HMB-001, in clinical development for blood clotting disorders. The company has raised substantial funding in recent years and has reported $185.5 million in cash reserves by the end of 2025.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.bioxconomy.com/investment/seaport-and-hemab-set-to-go-public-amid-biotech-ipo-resurgence
